Peer-reviewed veterinary case report
Radiation retreatment helps dogs with nasal cancer live longer
By Gieger, Tracy et al.·Published in Journal of the American Animal Hospital Association·2013·Department of Veterinary Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Reirradiation of canine nasal carcinomas treated with coarsely fractionated radiation protocols: 37 cases.
- Species:
- dog
Plain-English summary
A group of 37 dogs with nasal tumors received radiation therapy to treat their cancer. After the first round of treatment, all the dogs showed improvement, with 11 experiencing complete relief from symptoms for about 114 days. When their symptoms returned, many were given a second round of radiation, which helped 70% of them again. While some dogs developed mild eye problems from the treatment, the overall survival time was encouraging, averaging about 15 months after the first treatment.
People also search for: dog nasal cancer treatment · radiation therapy for dogs · canine nasal carcinoma symptoms · dog eye problems after radiation
Abstract
Data from 37 dogs with nasal carcinomas treated with two or more coarsely fractionated courses of radiation therapy (RT) were retrospectively reviewed. The median radiation dose for the first course of RT was 24 Gray (Gy). All dogs clinically responded, and 11 had complete resolution of signs for a median of 114 days. Dogs were retreated at relapse, with a median dose of 20 Gy, and 26 of 37 dogs (70%) had clinical responses. The second course of RT was initiated at a median of 150 days following completion of the first course. Side effects were mild: four dogs had chronic ocular conditions necessitating medication, one of which required enucleation. Median survival time (ST) from the first dose of RT was 453 days and 180 days from the first dose of the second course of RT. The following factors were examined but were not significant for survival: total RT dose, dose of the first course of RT, complete resolution of clinical signs, use of either chemotherapy or nonsteroidal anti-inflammatory drugs (NSAIDs), and stage (T1/T2 versus T3/T4). Dogs responded well to reirradiation with a subset experiencing chronic ocular side effects.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/23861260/